Advertisement
U.S. Markets open in 56 mins

Citius Oncology, Inc. (CTOR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0300-0.1200 (-10.43%)
At close: 04:00PM EST
1.0500 +0.02 (+1.94%)
After hours: 07:44PM EST

Citius Oncology, Inc.

420 Lexington Avenue
Suite 2446
New York, NY 10170
United States
347-627-0058

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 

Key Executives

NameTitlePayExercisedYear Born
Mr. Leonard L. MazurChairman, CEO & PresidentN/AN/A1945
Mr. Jaime BartushakCFO & TreasurerN/AN/A1968
Dr. Myron S. Czuczman M.D.Chief Medical OfficerN/AN/A1960
Mr. Myron Z. HolubiakSecretary & DirectorN/AN/A1947
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Corporate Governance

Citius Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.